Tech Transfer Deals, April 2016
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced February through March 2016.
You may also be interested in...
Deals in Depth July 2023
Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.
Dealmaking Quarterly Statistics, Q2 2023
During Q2, biopharma merger and acquisition deal value reached $29bn and drew in $36.8bn in potential deal value from alliances. Device company M&A values reached $988m, while in vitro diagnostics and research tools players’ M&A activity totaled $450m.
Financing Quarterly Statistics, Q2 2023
During Q2, biopharmas brought in an aggregate $23.8bn in financing and device company fundraising totaled $2.4bn; while in vitro diagnostic firms and research tools players raised $684m.